BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
Jun 07, 2010
 |  BC Extra  |  Clinical News

Wilex reports final Mesupron data

Wilex AG (Xetra:WL6) said 200 and 400 mg daily oral Mesupron plus weekly IV Gemzar gemcitabine led to overall response rates of 7.1% and 12.9%, respectively, vs. 3.8% for Gemzar alone in a Phase II trial to treat pancreatic cancer. Mesupron...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >